Famciclovir, an antiviral prodrug of penciclovir, remains a cornerstone in the treatment of herpesvirus infections, including herpes zoster (shingles), genital herpes, and cold sores. Marketed originally under the brand name Famvir by Novartis, this guanosine analogue antiviral has become widely available as a generic product across global markets. For pharmaceutical manufacturers, API producers, and traders, understanding the landscape of global Famciclovir buyers is essential for successful market penetration and sustainable business growth. The global Famciclovir professional market was valued at US$13.98 billion in 2025 and is projected to reach US$25.13 billion by 2034, registering a compound annual growth rate of 6.73%. The Famciclovir API market alone is estimated at approximately…